To hear about similar clinical trials, please enter your email below
Trial Title:
Pyrotinib and Subcutaneous Preparation of Trastuzumab Combined With Capecitabine Neoadjuvant Therapy for HER2+ Study of Breast Cancer
NCT ID:
NCT06483386
Condition:
Breast Cancer
Conditions: Official terms:
Breast Neoplasms
Capecitabine
Trastuzumab
Study type:
Interventional
Study phase:
Phase 2
Overall status:
Not yet recruiting
Study design:
Allocation:
N/A
Intervention model:
Single Group Assignment
Primary purpose:
Treatment
Masking:
None (Open Label)
Intervention:
Intervention type:
Drug
Intervention name:
Pyrotinib and Subcutaneous preparation of trastuzumab combined with capecitabine
Description:
Pyrotinib and Subcutaneous preparation of trastuzumab combined with capecitabine
Arm group label:
Treatment group
Summary:
Objective: To explore the efficacy and safety of Pyrotinib, trastuzumab subcutaneous
preparation and capecitabine neoadjuvant therapy for early HER2+breast cancer.
Administration method: 6 cycles throughout the entire process:
Pyrotinib Maleate Tablets: Continuously administered from the first day of the first
course of treatment, 400 Mg/day, orally administered within 30 minutes after breakfast
Trastuzumab: Subcutaneous injection, 600mg, d1, q3w Capecitabine: oral, 1000 mg/m2, bid
d1-14, q3w Premenopausal goserelin 3.6mg once every 28 days
Detailed description:
Inclusion Criteria :1. Age: Female first-time patients aged 18 and above; 2. Pathological
examination confirmed HER2 positive invasive breast cancer; (HER2 positive definition)
Further application of in situ hybridization (ISH) for immunohistochemistry (IHC) 3+or
IHC 2+ HER2 gene amplification, regardless of hormone receptor status (ER and PR);
According to the eighth edition of AJCC, the staging is T1c-2N0-1M0, and according to
Recipe 1.1, there are At least one measurable lesion; 4. ECOG PS: 0-1 points; 5. The main
organ function is normal, which meets the following standards:
1. The standard for blood routine examination must comply with (no blood transfusion or
blood products within 14 days, no use of G-CSF)
Correction of other hematopoietic stimulating factors:
Hb≥100g/L； ANC ≥ 1.5 × 10 9/L; PLT ≥ 100 × 10 9/L;
2. Biochemical examination must meet the following standards:
TBIL ≤ 1 × ULN; ALT, AST ≤ 1.5 × ULN; ALP ≤ 2.5 × ULN; BUN and Cr ≤ 1.5 × ULN;
3. Cardiac ultrasound:
Left ventricular ejection fraction (LVEF) ≥ 55%; 6. Women of childbearing age must
undergo a pregnancy test (serum) within 7 days before enrollment, and the result is
negative Sexual and willing to use appropriate medication during the trial period and
within 8 weeks after the last administration of the investigational drug The method of
contraception; 7. The subjects voluntarily joined this study, signed an informed consent
form, had good compliance, and cooperated with follow-up.
Exclusion criteria:
Those who are unable to participate in the clinical study under any of the following
circumstances:
1. Have received any form of anti-tumor treatment in the past (chemotherapy,
radiotherapy, molecular targeted therapy,...) Endocrine therapy, etc;
2. Simultaneously receiving any other anti-tumor treatment;
3. Bilateral breast cancer, inflammatory breast cancer or occult breast cancer;
4. breast cancer not confirmed by histopathology;
5. Other malignant tumors have appeared within the past 5 years, except for cured
cervical cancer in situ;
6. Severe dysfunction of important organs such as heart, liver, and kidney;
7. Unable to swallow, chronic diarrhea, and intestinal obstruction, there are various
factors that affect medication administration and absorption Factors;
8. Participated in clinical trials of other drugs within 4 weeks prior to enrollment;
9. Individuals with a known history of allergies to the drug components of this
protocol; History of immunodeficiency, including HIV Test positive, HCV, active
hepatitis B, or other acquired diseases Natural immunodeficiency disease or a
history of organ transplantation;
10. Have ever suffered from any heart disease, including: (1) those that require
medication or have clinical significance Arrhythmias; (2) Myocardial infarction; (3)
Heart failure; (4) Any researcher Other heart diseases deemed unsuitable for
participation in this trial;
11. Pregnant and lactating female patients with fertility and positive baseline
pregnancy test results Female patients of childbearing age who are unwilling to take
effective contraceptive measures throughout the entire trial period Female patients;
12. According to the researcher's judgment, there is a serious threat to patient
safety or an impact on patient completion of the study The accompanying diseases
studied (including but not limited to severe hypertension that cannot be controlled
by medication, severe Diabetes, active infection, etc.);
13. Have a clear history of neurological or psychiatric disorders, including epilepsy or
dementia. Researchers believe that Any other circumstances in which the patient is
not suitable to participate in this study.
Termination of study standard:
1. Completed treatment according to regulations;
2. Imaging evidence indicates progression of the disease;
3. After dose adjustment, the subjects still cannot tolerate toxicity; During the
research process, pregnancy events occurred in the subjects;
5. The subject withdraws their informed consent and requests withdrawal; 6. Other
situations where the researcher deems it necessary to withdraw from the study.
efficacy indicators:
Main efficacy indicators:
tpCR
Secondary efficacy indicators:
1. pCR（ypT0yp0）
2. BCS
3. ORR
4. iDFS
5. EFS
6. Security
7. Biomarker detection
Research object： T1c-2N0-1M0 HER2 expression positive in newly treated female patients
Criteria for eligibility:
Criteria:
Inclusion Criteria:
1. Age: Female first-time patients aged 18 and above;
2. Pathological examination confirmed HER2 positive invasive breast cancer; (HER2
positive definition) Further application of in situ hybridization (ISH) for
immunohistochemistry (IHC) 3+or IHC 2+HER2 gene amplification, regardless of hormone
receptor status (ER and PR);
3. According to the eighth edition of AJCC, the staging is T1c-2N0-1M0, and according
to Recipe 1.1, there are At least one measurable lesion;
4. ECOG PS: 0-1 points;
5. The main organ function is normal, which meets the following standards:
1) The standard for blood routine examination must comply with (no blood transfusion or
blood products within 14 days, no use of G-CSF) Correction of other hematopoietic
stimulating factors:Hb≥100g/L ;ANC≥1.5×109/L；PLT≥100×109/L；2) Biochemical
examination must meet the following standards:TBIL≤1×ULN； ALT, AST ≤ 1.5 × ULN;
ALP≤2.5×ULN； BUN and Cr ≤ 1.5 × ULN;3) Cardiac ultrasound:Left ventricular ejection
fraction (LVEF) ≥ 55%; 6. Women of childbearing age must undergo a pregnancy test
(serum) within 7 days before enrollment, and the result is negative Sexual and
willing to use appropriate medication during the trial period and within 8 weeks
after the last administration of the investigational drug The method of
contraception; 7. The subjects voluntarily joined this study, signed an informed
consent form, had good compliance, and cooperated with follow-up.
Exclusion Criteria:
1. Have received any form of anti-tumor treatment in the past (chemotherapy,
radiotherapy, molecular targeted therapy,...)Endocrine therapy, etc;
2. Simultaneously receiving any other anti-tumor treatment;
3. Bilateral breast cancer, inflammatory breast cancer or occult breast cancer;
4. breast cancer not confirmed by histopathology;
5. Other malignant tumors have appeared within the past 5 years, except for cured
cervical cancer in situ;
6. Severe dysfunction of important organs such as heart, liver, and kidney;
7. Unable to swallow, chronic diarrhea, and intestinal obstruction, there are various
factors that affect medication administration and absorption factor;
8. Participated in clinical trials of other drugs within 4 weeks prior to enrollment;
9. Individuals with a known history of allergies to the drug components of this
protocol; History of immunodeficiency, including HIV Test positive, HCV, active
hepatitis B, or other acquired diseases Natural immunodeficiency disease or a
history of organ transplantation;
10. Have ever suffered from any heart disease, including: (1) those that require
medication or have clinical significance Arrhythmias; (2) Myocardial infarction; (3)
Heart failure; (4) Any researcher Other heart diseases deemed unsuitable for
participation in this trial;
11. Pregnant and lactating female patients with fertility and positive baseline
pregnancy test results Female patients of childbearing age who are unwilling to take
effective contraceptive measures throughout the entire trial period Female patients;
12. According to the researcher's judgment, there is a serious threat to patient safety
or an impact on patient completion of the study The accompanying diseases studied
(including but not limited to severe hypertension that cannot be controlled by
medication, severe Diabetes, active infection, etc.);
13. Have a clear history of neurological or psychiatric disorders, including epilepsy or
dementia. Researchers believe that Any other circumstances in which the patient is
not suitable to participate in this study.
Gender:
Female
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Start date:
July 15, 2024
Completion date:
December 30, 2026
Lead sponsor:
Agency:
Tianjin Medical University Cancer Institute and Hospital
Agency class:
Other
Source:
Tianjin Medical University Cancer Institute and Hospital
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT06483386
